20 completed, 4 terminated, 1 withdrawn. 13 Phase 2, 12 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 10, Terminated 2, Withdrawn 1 |
| Phase 1 | 12 | Completed 10, Terminated 2 |
Follow Akros Pharma Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS) JTE-162 - Cryopyrin-associated Periodic Syndromes (CAPS) | Phase 1 | Completed | Akros Pharma Inc. | 5 | 2026-02-02 | 2026-10-09 |
| Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction JTT-861 Capsules, Placebo Capsules - Chronic Heart Failure | Phase 2 | Completed | Akros Pharma Inc. | 314 | 2023-12-20 | 2026-09-24 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes JTT-662, Placebo - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Akros Pharma Inc. | 37 | 2020-06-15 | 2023-01-27 |
| Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension JTT-251, Placebo - Pulmonary Arterial Hypertension | Phase 2 | Withdrawn | Akros Pharma Inc. | 2019-03-01 | 2019-05-03 | |
| Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis JTE-451 Tablets, Placebo Tablets - Plaque Psoriasis, Psoriasis | Phase 2 | Completed | Akros Pharma Inc. | 152 | 2019-01-17 | 2021-08-20 |
| Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis JTE-051, Placebo - Plaque Psoriasis, Skin Diseases | Phase 2 | Terminated | Akros Pharma Inc. | 13 | 2017-11-10 | 2021-08-06 |
| Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects JTE-451, Placebo - Plaque Psoriasis, Psoriasis | Phase 1 | Completed | Akros Pharma Inc. | 47 | 2016-12-01 | 2017-07-02 |
| Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis JTE-051, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Akros Pharma Inc. | 260 | 2016-09-14 | 2021-06-14 |
| Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis JTZ-951, 14C-JTZ-951 - Anemia of Chronic Kidney Disease | Phase 1 | Completed | Akros Pharma Inc. | 6 | 2016-06-01 | 2016-11-29 |
| Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease JTZ-951, Lapatinib - Anemia of Chronic Kidney Disease | Phase 1 | Completed | Akros Pharma Inc. | 10 | 2015-10-01 | 2016-04-28 |
| Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252 JTT-252 or Placebo, JTT-252 - Diabetes Mellitus | Phase 1 | Terminated | Akros Pharma Inc. | 85 | 2014-04-01 | 2015-05-01 |
| Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects JTT-251 or Placebo - Diabetes Mellitus | Phase 1 | Completed | Akros Pharma Inc. | 94 | 2014-03-01 | 2014-10-07 |
| Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease JTZ-951 - Anemia in Chronic Kidney Disease | Phase 1 | Completed | Akros Pharma Inc. | 6 | 2013-10-01 | 2014-03-18 |
| Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease JTZ-951, Placebo - Anemia of Chronic Kidney Disease | Phase 1 | Completed | Akros Pharma Inc. | 29 | 2013-05-01 | 2014-07-14 |
| Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus JTT-851, Glimepiride, Placebo for Active - Type 2 Diabetes Mellitus | Phase 2 | Completed | Akros Pharma Inc. | 325 | 2012-09-01 | 2013-08-01 |
| Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects JTK-853, Dose 2 JTK-853, Dose 3 JTK-853 - Hepatitis C Virus Infection, Response to Therapy of | Phase 1 | Completed | Akros Pharma Inc. | 29 | 2010-08-01 | 2011-11-21 |
| Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects JTK-853, ketoconazole, JTK-853 or Placebo - Healthy | Phase 1 | Terminated | Akros Pharma Inc. | 41 | 2010-03-01 | 2011-11-21 |
| Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects JTK-853 or Placebo - Healthy | Phase 1 | Completed | Akros Pharma Inc. | 70 | 2010-01-01 | 2011-11-22 |
| Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients JTT-654, JTT-654 Placebo - Type II Diabetes Mellitus | Phase 2 | Terminated | Akros Pharma Inc. | 152 | 2009-09-01 | 2013-02-04 |
| Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients JTT-130, JTT-130 Placebo - Type II Diabetes Mellitus | Phase 2 | Completed | Akros Pharma Inc. | 496 | 2009-06-01 | 2013-02-04 |
Showing 20 of 25. Sign in to see all of them.
Diabetes Mellitus (6) · Diabetes Mellitus, Type 2 (4) · Dyslipidemias (4) · Psoriasis (3) · Skin Diseases (3) · Anemia (1) · Arthritis, Rheumatoid (1) · Cryopyrin-Associated Periodic Syndromes (1) · Heart Failure (1) · Hepatitis C (1) · Hyperlipoproteinemia Type II (1) · Kidney Failure, Chronic (1) · Pulmonary Arterial Hypertension (1) · Renal Insufficiency, Chronic (1)
enarodustat (4) · JTK-853 (3) · dalcetrapib (3) · Atorvastatin (1) · Exercise (1) · Ketoconazole (1) · Lapatinib (1) · Pravastatin (1) · Simvastatin (1) · diethyl 2-((3-dimethylcarbamoyl-4-((4'-trifluoromethylbiphenyl-2-carbonyl)amino)phenyl)acetyloxymethyl)-2-phenylmalonate (1) · glimepiride (1)
United States (18) · Canada (4) · Netherlands (4) · Poland (3) · Bulgaria (2) · Czechia (2) · Romania (2) · Russia (2) · Argentina (1) · Colombia (1) · Hungary (1) · Mexico (1) · Peru (1) · Puerto Rico (1) · Spain (1)
Hideyuki Yamamoto (3) · Shoji Hoshino, D.V.M (3) · Hisashi Kodama, Ph.D. (1) · Yoshiro Masuda (1) · Yuichiro Neki (1)